Company profile
IntelliPalp Dx | Prostate cancer diagnosis
IntelliPalpDx provides more accurate prostate cancer diagnosis at an early stage
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
GAZ1(A) | Transaction MzUxMzg3MTgxNmFkaXF6a2N4 | Paper/PDF filed
Published 03 Apr 2026 23:12
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
IntelliPalp Dx researches and develops medical devices to assist with clinical diagnosis of prostate cancer.
Established in 2020, IntelliPalp Dx is a spinout company from Heriot-Watt and Edinburgh Universities with NHS Lothian. The company has been established to develop the commercial opportunities arising from a research collaboration between Professor Bob Reuben (HWU) and Professor Alan McNeill (NHS Lothian/University of Edinburgh) that has spanned two decades. The research has provided a method for mechanical palpation of human tissue that provides information about the morphology of that tissue, specifically whether cancer is present or not (maybe included some references/links to open access publications). The work has focused on the diagnosis of prostate cancer and has provided the basis for the ProstaPalp™ device that will soon enter a validation study to confirm its accuracy as a diagnostic tool for prostate cancer. IntelliPalp Dx specialises in instrumented palpitation and the diagnosis and management of prostate cancer. Its founders are Professor Alan McNeill, Consultant Urological Surgeon; Mr Daniel Good, Consultant Urological Surgeon; Professor Bob Reuben, Professor of Materials Engineering at Heriot-Watt University; Ms Femi Johnson, Engineer; Professor David Sigsworth FRSE; Mr Philip Rainey, Interim CEO. The company's first product is ProstaPalp, a device that offers an objective test for improved prostate cancer diagnosis and management.
New company so no impacts as yet. Company has employees and has been awarded funding but actual impact will be reported in 2022.
